Objective The purpose of writing the"expert consensus on humanistic care for patients in hospice care"(hereinafter referred to as the"consensus")aims to standardize the practice of humanistic care in the field of hospice care,ensuring that humanistic care is integrated throughout the entire service process for hospice care patients and their families.Methods A systematic search was conducted in domestic and foreign databases for literature related to hospice care and humanistic care,including guidelines,expert consensuses,systematic reviews or Meta-analyses,and evidence summaries.High-quality evidence was evaluated,extracted,and summarized to form the initial draft of the"consensus".From June to October 2024,20 experts from the fields of hospice care,nursing humanities,and evidence-based nursing were invited to participate in 1 round of expert consultation.Among them,13 experts were selected for 2 rounds of expert demonstration meetings.After collating and analyzing the experts' opinions,the initial draft was revised and refined,ultimately resulting in the final version of the"consensus".Results The effective response rate of the consultation questionnaire was 100％,with expert authority coefficient of 0.880,judgment coefficient of 0.935,and familiarity level of 0.825.The Kendall harmony coefficient of the expert consultation was 0.134(P＜0.05).The"consensus"consisted of 13 aspects,including the targets and objectives,principles,institutional guarantees,environmental requirements,etc.Conclusion This"consensus"possesses strong scientific rigor and practicality,which can provide guidance and references for the practice of humanistic care in the field of hospice care,promoting the standardization and humanization of hospice care services.

Objective To analyze correlation of endolymphatic hydrops (EH) in the inner ear with age in Meniere’s disease (MD) patients. Methods A retrospective analysis were underwent in 101 definite unilateral MD patients. They were divided into young-age (＜18 years old) group, middle-age (18-45 years old) group and elder-age (＞45 years old) group. All patients underwent inner ear three-dimensional inversion-recovery with real reconstruction (3D-real IR) imaging 4 hours after intravenous gadolinium injection. EH rates among different groups were compared. Results The positive rates of EH in the young-age group, middle-age group and elder-age group were 68.2% (15/22), 54.5% (18/33) and 56.5% (26/46), respectively (P＝0.567). There was no difference in the positive rates of EH in vestibule and cochlea among three groups. There was no difference in the rates of mild and significant EH in vestibule and cochlea among three groups. Conclusions Age might not be related to the occurrence of EH in the inner ear in MD patients.

Objective:To investigate the efficacy and toxicity of blinatumomab in the first-line and second-line treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL).Methods:A multi-center retrospective cohort study was conducted to analyze clinical data from 323 pediatric B-ALL patients treated with blinatumomab across 14 hospitals in China from May 2021 to July 2023. Patients were divided into four groups based on the treatment phase and disease status when blinatumomab was used: relapsed/refractory group, post-consolidation minimal residual disease (MRD)-positive group, early MRD-positive group, and MRD-negative group. Blinatumomab for the relapsed/refractory group was considered as second-line treatment, while the other 3 groups as first-line treatment. The MRD negativity rate after treatment, the survival rates and the incidence of severe adverse events were compared across these groups. Patients who received blinatumomab for more than 7 days were included in the efficacy analysis. Survival analysis was performed using the Kaplan-Meier method, and Log-Rank test was used to compare the survival rates among groups.Results:Among the 323 patients, 191 (59.1%) were male, with the age of 6.2 (3.9, 10.5) years. There were 117 patients in the relapsed/refractory group, 62 cases in the post-consolidation MRD-positive group, 43 cases in the early MRD-positive group, and 101 cases in the MRD negative group. In the relapsed/refractory group, the complete remission rate and MRD negativity rate after one course of blinatumomab were 71.4% (35/49) and 81.5% (75/92) for the 49 children without complete remission and the 92 children with flow cytometry-positive MRD, respectively. In the post-consolidation MRD-positive group, the MRD negativity rates after one course of blinatumomab were 100.0% (27/27), 12/16 and 9/19 for patients with MRD positivity detected by flow cytometry, polymerase chain reaction and next-generation sequencing, respectively. In the early MRD-positive group, the MRD negativity rates were 96.7% (29/30) and 9/9 for flow cytometry and next-generation sequencing, respectively. The 2-year overall survival rate and event-free survival rate for the 319 children evaluable for efficacy were (90.6±1.7)% and (87.6±1.9)%, respectively, with the relapsed/refractory group showing significantly lower overall survival rates and event-free survival rate compared to the other groups ( χ2=21.40, 26.21,both P<0.001). Grade 3 or higher adverse events occurred in 128 cases (39.6%), with hematological toxicity observed in 101 cases, while cytokine release syndrome (CRS), infection, and neurotoxicity occurred in 11, 26 and 8 cases, respectively. In addition, there were statistically significant differences in the grade 3 or higher CRS among the four groups ( χ2=8.03, P<0.05). Conclusion:Blinatumomab can clear MRD more effectively and achieve superior survival outcomes when used as first-line treatment for pediatric B-ALL, with less CRS.

Objective The purpose of writing the"expert consensus on humanistic care for patients in hospice care"(hereinafter referred to as the"consensus")aims to standardize the practice of humanistic care in the field of hospice care,ensuring that humanistic care is integrated throughout the entire service process for hospice care patients and their families.Methods A systematic search was conducted in domestic and foreign databases for literature related to hospice care and humanistic care,including guidelines,expert consensuses,systematic reviews or Meta-analyses,and evidence summaries.High-quality evidence was evaluated,extracted,and summarized to form the initial draft of the"consensus".From June to October 2024,20 experts from the fields of hospice care,nursing humanities,and evidence-based nursing were invited to participate in 1 round of expert consultation.Among them,13 experts were selected for 2 rounds of expert demonstration meetings.After collating and analyzing the experts' opinions,the initial draft was revised and refined,ultimately resulting in the final version of the"consensus".Results The effective response rate of the consultation questionnaire was 100％,with expert authority coefficient of 0.880,judgment coefficient of 0.935,and familiarity level of 0.825.The Kendall harmony coefficient of the expert consultation was 0.134(P＜0.05).The"consensus"consisted of 13 aspects,including the targets and objectives,principles,institutional guarantees,environmental requirements,etc.Conclusion This"consensus"possesses strong scientific rigor and practicality,which can provide guidance and references for the practice of humanistic care in the field of hospice care,promoting the standardization and humanization of hospice care services.

Objective To explore the expression and prognostic value of Smad ubiquitination regulator 2(SMURF2)and protein kinase C receptor 1(RACK1)in epithelial ovarian cancer(EOC)tissues.Methods Cancer tissue specimens of 112 patients with EOC(EOC group)admitted to the hospital from January 2019 to Janu-ary 2021,as well as normal ovarian tissue specimens of 60 patients with other ovarian diseases(control group)who underwent ovarian surgery in the same hospital during the same period were selected.The expressions of SMURF2 and RACK1 in EOC cancer tissues and normal ovarian tissues were detected by real-time fluores-cence quantitative PCR and immunohistochemistry.Pearson correlation analysis was used to analyze the rela-tionship between the expressions of SMURF2 mRNA and RACK1 mRNA in EOC cancer tissues.The Kaplan-Meier survival curve and Log-rank test were used to analyze the differences in survival prognosis among pa-tients with different expressions of SMURF2 and RACK1.Multivariate COX regression analysis was conduc-ted to analyze the influencing factors of survival prognosis in EOC.Results The expression level of SMURF2 mRNA in EOC cancer tissues was lower than that in normal ovarian tissues,and the expression level of RACK1 mRNA was higher than that in normal ovarian tissues,and the differences were statistically signifi-cant(P＜0.05).The expression levels of SMURF2 mRNA and RACK1 mRNA in EOC cancer tissues were negatively correlated(r=-0.764,P＜0.001).The positive rate of SMURF2 in EOC cancer tissues was lower than that in normal ovarian tissues,and the positive rate of RACK1 was higher than that in normal ovarian tis-sues.The difference was statistically significant(P＜0.001).Compared with the cancer tissues of EOC pa-tients with International Federation of Obstetrics and Gynecology(FIGO)stage Ⅰ-Ⅱ and no lymph node metastasis,the positive rate of SMURF2 was lower and the positive rate of RACK1 was higher in the cancer tissues of EOC patients with FIGO stage Ⅲ and lymph node metastasis,and the differences were statistically significant(P＜0.05).The 3-year overall survival rate of EOC patients in the SMURF2 positive group was higher than that in the negative group,and the 3-year overall survival rate of EOC patients in the RACK1 pos-itive group was lower than that in the negative group,and the differences were statistically significant(Log-Rank x2=4.938,5.251;P=0.028,0.018).FIGO stage Ⅲ,lymph node metastasis and positive RACK1 were risk factors affecting the survival prognosis of EOC(P＜0.001),while positive SMURF2 was a protective fac-tor(P＜0.001).Conclusion The expression level of SMURF2 is decreased and the expression level of RACK1 is increased in EOC cancer tissues.Both are related to FIGO stage and lymph node metastasis,and are markers for evaluating the survival prognosis of EOC patients.

Objective:To evaluate the quality of life in patients with psoriasis across varying levels of psychological resilience.Methods:A cross-sectional study was conducted, employing a convenient sampling method to recruit 390 psoriasis patients from Beijing University of Chinese Medicine Dongzhimen Hospital from February to August 2023. The sample included 57 male and 333 female patients, with a mean age of (24.9±5.4) years. Participants were guided through questionnaire completion using a standardized protocol by trained investigators. Patients were stratified into three groups based on the Connor-Davidson Resilience Scale (CD-RISC-10): low ( n=53), moderate ( n=251), and high ( n=86) psychological resilience. The dermatology life quality index (DLQI) was utilized to assess quality of life across six domains: symptom perception, daily activities, leisure and recreation, work and study, interpersonal relationships, and treatment. Results:The total scores for the DLQI among psoriasis patients with low, moderate, and high psychological resilience were 10.05 (6.75, 15.00), 7.00 (4.00, 11.00), and 5.00 (2.00, 10.00), respectively. Symptom perception scores were 3.00 (2.00, 4.00), 2.00 (2.00, 4.00), and 2.00 (1.00, 3.00), respectively. Scores for daily activities were 2.00 (2.00, 4.00), 1.00 (1.00, 2.00), and 1.00 (0.00, 2.00), respectively. Leisure and recreation scores were 2.00 (1.00, 3.00), 1.00 (0.00, 3.00), and 1.00 (0.00, 2.00), respectively. Work and study scores were 1.00 (0.00, 3.00), 0.00 (0.00, 1.00), and 0.00 (0.00, 1.00), respectively. Interpersonal relationship scores were 1.00 (0.00, 2.00), 0.00 (0.00, 1.00), and 0.00 (0.00, 1.00), respectively. Treatment scores were 1.00 (0.00, 1.25), 0.00 (0.00, 1.00), and 0.00 (0.00, 1.00), respectively. Statistically significant differences were observed in the total DLQI scores and individual item scores among the three groups (all P<0.05), with patients exhibiting high psychological resilience demonstrating superior quality of life. Conclusion:This study demonstrates statistically significant differences in the quality of life among psoriasis patients with varying psychological resilience levels, and those exhibiting higher resilience demonstrate superior quality of life.

Objective:To investigate the efficacy and toxicity of blinatumomab in the first-line and second-line treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL).Methods:A multi-center retrospective cohort study was conducted to analyze clinical data from 323 pediatric B-ALL patients treated with blinatumomab across 14 hospitals in China from May 2021 to July 2023. Patients were divided into four groups based on the treatment phase and disease status when blinatumomab was used: relapsed/refractory group, post-consolidation minimal residual disease (MRD)-positive group, early MRD-positive group, and MRD-negative group. Blinatumomab for the relapsed/refractory group was considered as second-line treatment, while the other 3 groups as first-line treatment. The MRD negativity rate after treatment, the survival rates and the incidence of severe adverse events were compared across these groups. Patients who received blinatumomab for more than 7 days were included in the efficacy analysis. Survival analysis was performed using the Kaplan-Meier method, and Log-Rank test was used to compare the survival rates among groups.Results:Among the 323 patients, 191 (59.1%) were male, with the age of 6.2 (3.9, 10.5) years. There were 117 patients in the relapsed/refractory group, 62 cases in the post-consolidation MRD-positive group, 43 cases in the early MRD-positive group, and 101 cases in the MRD negative group. In the relapsed/refractory group, the complete remission rate and MRD negativity rate after one course of blinatumomab were 71.4% (35/49) and 81.5% (75/92) for the 49 children without complete remission and the 92 children with flow cytometry-positive MRD, respectively. In the post-consolidation MRD-positive group, the MRD negativity rates after one course of blinatumomab were 100.0% (27/27), 12/16 and 9/19 for patients with MRD positivity detected by flow cytometry, polymerase chain reaction and next-generation sequencing, respectively. In the early MRD-positive group, the MRD negativity rates were 96.7% (29/30) and 9/9 for flow cytometry and next-generation sequencing, respectively. The 2-year overall survival rate and event-free survival rate for the 319 children evaluable for efficacy were (90.6±1.7)% and (87.6±1.9)%, respectively, with the relapsed/refractory group showing significantly lower overall survival rates and event-free survival rate compared to the other groups ( χ2=21.40, 26.21,both P<0.001). Grade 3 or higher adverse events occurred in 128 cases (39.6%), with hematological toxicity observed in 101 cases, while cytokine release syndrome (CRS), infection, and neurotoxicity occurred in 11, 26 and 8 cases, respectively. In addition, there were statistically significant differences in the grade 3 or higher CRS among the four groups ( χ2=8.03, P<0.05). Conclusion:Blinatumomab can clear MRD more effectively and achieve superior survival outcomes when used as first-line treatment for pediatric B-ALL, with less CRS.

Objective:To evaluate the quality of life in patients with psoriasis across varying levels of psychological resilience.Methods:A cross-sectional study was conducted, employing a convenient sampling method to recruit 390 psoriasis patients from Beijing University of Chinese Medicine Dongzhimen Hospital from February to August 2023. The sample included 57 male and 333 female patients, with a mean age of (24.9±5.4) years. Participants were guided through questionnaire completion using a standardized protocol by trained investigators. Patients were stratified into three groups based on the Connor-Davidson Resilience Scale (CD-RISC-10): low ( n=53), moderate ( n=251), and high ( n=86) psychological resilience. The dermatology life quality index (DLQI) was utilized to assess quality of life across six domains: symptom perception, daily activities, leisure and recreation, work and study, interpersonal relationships, and treatment. Results:The total scores for the DLQI among psoriasis patients with low, moderate, and high psychological resilience were 10.05 (6.75, 15.00), 7.00 (4.00, 11.00), and 5.00 (2.00, 10.00), respectively. Symptom perception scores were 3.00 (2.00, 4.00), 2.00 (2.00, 4.00), and 2.00 (1.00, 3.00), respectively. Scores for daily activities were 2.00 (2.00, 4.00), 1.00 (1.00, 2.00), and 1.00 (0.00, 2.00), respectively. Leisure and recreation scores were 2.00 (1.00, 3.00), 1.00 (0.00, 3.00), and 1.00 (0.00, 2.00), respectively. Work and study scores were 1.00 (0.00, 3.00), 0.00 (0.00, 1.00), and 0.00 (0.00, 1.00), respectively. Interpersonal relationship scores were 1.00 (0.00, 2.00), 0.00 (0.00, 1.00), and 0.00 (0.00, 1.00), respectively. Treatment scores were 1.00 (0.00, 1.25), 0.00 (0.00, 1.00), and 0.00 (0.00, 1.00), respectively. Statistically significant differences were observed in the total DLQI scores and individual item scores among the three groups (all P<0.05), with patients exhibiting high psychological resilience demonstrating superior quality of life. Conclusion:This study demonstrates statistically significant differences in the quality of life among psoriasis patients with varying psychological resilience levels, and those exhibiting higher resilience demonstrate superior quality of life.

Objective To explore the relationship between serum long non-coding RNA hypoxia-inducible factor 1 alpha antisense RNA 1(lncRNA HIFA1-AS1),CXC chemokine ligand 9(CXCL9)and disease severity,adverse pregnancy outcome in patients with preeclampsia.Methods A total of 83 patients with preeclampsia admitted to Xi'an Gaoxin Hospital January 2021 to December 2022 were taken as preeclampsia group,According to the time of diagnosis,patients with preeclampsia were divided into early onset preeclampsia group(n=39)and late onset preeclampsia group(n=44).According to the severity of the condition,patients with preeclampsia were divided into two groups:mild preeclampsia group(n=51)and severe preeclampsia group(n=32).According to pregnancy outcomes,they were divided into a normal pregnancy outcome group(n=56)and an adverse pregnancy outcome group(n=27).At the same time,60 healthy pregnant women with pregnancy were collected as control group.Real-time fluorescence quantitative PC(qRT-PCR)was used to detect serum lncRNA HIF1A-AS1,and enzyme-linked immunosorbent assay(ELISA)was used to detect serum CXCL9.Spearman rank correlation analysis was used to analyze the association between serum lncRNA HIF1A-AS1,CXCL9 and severity of disease.Logistic regression analysis was used to analyze the factors influencing the adverse pregnancy outcome in patients with preeclampsia.ROC curve was drawn to assess the predictive value of serum lncRNA HIF1A-AS1,CXCL9 for adverse pregnancy outcome.Results The relative expression of serum lncRNA HIF1A-AS1(0.73±0.26)in preeclampsia group was lower than that(1.15±0.34)in control group,and CXCL9 level(209.34±45.34 pg/ml)higher than that(116.80±37.76 pg/ml)in control group,the differences were statistically significant(t=8.379,12.903,all P<0.05).The relative expression of serum lncRNA HIF1A-AS1(0.58±0.21)in early-onset preeclampsia group was lower than that in late-onset preeclampsia group(0.86±0.27),and CXCL9 level(236.60±31.02 pg/ml)higher than that in late-onset preeclampsia group(185.18±23.63 pg/ml),the differences were statistically significant(t=5.226,8.551,all P<0.05).The relative expression of serum lncRNA HIF1A-AS1(0.52±0.21)in severe preeclampsia group was lower than that in late-onset preeclampsia group(0.97±0.34),and CXCL9 level(253.38±41.20 pg/ml)higher than that in late-onset preeclampsia group(159.65±40.79 pg/ml),the differences were statistically significant(t=6.409,10.152,all P<0.05).Serum lncRNA HIF1A-AS1 and CXCL9 were associated with condition of preeclampsia(r=-0.627,0.651,all P<0.05).CXCL9[OR(95%CI):1.581(1.098～2.276)]was independent risk factor for adverse pregnancy outcome in patients with preeclampsia(P<0.05).LncRNA HIF1A-AS1[OR(95%CI):0.806(0.673～0.965)]was a protective factor(P<0.05),and early-onset preeclampsia[OR(95%CI):1.390(1.088～1.775)]and severe preeclampsia[OR(95%CI):1.589(1.222～2.066)]were risk factors for adverse pregnancy outcome(all P<0.05).Serum lncRNA HIF1A-AS1,CXCL9 and indicators combined had predictive value for adverse pregnancy outcome in patients with preeclampsia,with AUC of 0.770,0.767 and 0.876,respectively.And the combined prediction AUC was better than single indicator,and differences were statistically significant(Z=2.455,2.398,all P<0.05).Conclusion Serum lncRNA HIF1A-AS1 expression is down-regulated and CXCL9 expression is up-regulated in patients with preeclampsia,both indicators are associated with severity of disease and adverse pregnancy outcome.Early detection of two indicators are expected to be markers for predicting adverse pregnancy outcome in patients with preeclampsia.

Objective:To improve the prognosis stratification, especially early mortality(EM), of elderly patients with newly diagnosed multiple myeloma(NDMM).Methods:In this retrospective study, univariate and multivariate Cox regression analysis were conducted to identify the independent prognostic factors associated with overall survival(OS)and the chi-square test and multivariate Logistic analysis were used to identify the prognostic factors associated with EM in 223 elderly patients(age≥65 years)with NDMM from three centers in the country.Results:Increased NT-pro-BNP(≥300 pg/ml), ECOG-PS≥2 and stage Ⅲ R-ISS were identified as three independent adverse prognostic factors of OS.The rates of EM3, EM6, EM12 and EM24 were 12.1%, 20.1%, 32.2% and 60%, respectively.The most common cause for EM6(particularly EM3)was disease-related complications resulting from ineligibility for treatment due to poor physical performance, severe organ dysfunction or treatment discontinuation due to treatment intolerance, while the most common cause for EM12(particularly EM24)was disease progression or relapse mainly as a result of inadequate treatment.R-ISS staging failed to predict EM, while decreased eGFR, ECOG-PS≥2, and increased NT-pro-BNP were able to estimate the risk of EM, with increased NT-pro-BNP as a common independent factor for EM12( P=0.03)and EM24( P=0.015). Conclusions:R-ISS staging, which primarily reflects MM biology, cannot predict EM.However, factors such as NT-pro-BNP, eGFR and ECOG-PS associated with frailty and impairment of organ functions can be used to estimate the risk of EM, among which NT-pro-BNP may be the most important independent factor for EM.Therefore, incorporation of these frailty-related biomarkers into R-ISS staging may be able to more precisely estimate the prognosis and particularly early death of elderly patients with NDMM.